Hostname: page-component-7b7567c8c-tnkh4 Total loading time: 0 Render date: 2026-11-19T04:47:31.786Z Has data issue: false hasContentIssue false

How are the sub-unit pertussis vaccines to be evaluated?

Published online by Cambridge University Press:  19 October 2009

D. N. Baxter
Affiliation:
Department of Community Medicine, Manchester University Medical School, Stopford Building, Oxford Road, Manchester M13 9PT, UK
A. C. C. Gibbs
Affiliation:
Department of Community Medicine, Manchester University Medical School, Stopford Building, Oxford Road, Manchester M13 9PT, UK
Rights & Permissions [Opens in a new window]

Summary

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.

Although an effective whooping cough vaccine has been available in the UK since the 1950s, its current association with neurotoxicity has resulted in poor uptake: as a consequence major epidemics (with significant morbidity and mortality) arc still being experienced.

Component (sub-unit) vaccines, which incorporate those antigens thought to be concerned with generating a protective effect, have been developed and are now available for field testing. This paper addresses how such a vaccine might be evaluated, the organization of a trial and the difficulties to be expected.

Information

Type
Research Article
Copyright
Copyright © Cambridge University Press 1987